SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-030865
Filing Date
2024-08-09
Accepted
2024-08-09 06:37:23
Documents
16
Period of Report
2024-08-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44441
2 ex1-1.htm EX-1.1 289041
3 ex5-1.htm EX-5.1 14569
4 ex5-1_001.jpg GRAPHIC 5895
  Complete submission text file 0001493152-24-030865.txt   596023

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ocx-20240809.xsd EX-101.SCH 3012
6 XBRL LABEL FILE ocx-20240809_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE ocx-20240809_pre.xml EX-101.PRE 22358
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3537
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

IRS No.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 241190348
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)